Toronto, Ontario – October 7, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has collaborated with Sigma-Aldrich Corporation’s (NASDAQ: SIAL) custom manufacturing services business unit SAFC® Commercial , in the manufacture of the Photo Dynamic Compounds (“PDCs”) being developed by Theralase for the destruction of cancer.
Under the terms of the agreement, SAFC will develop the Standard Operating Procedures (“SOPs”) to manufacture initial quantities of each of Theralase’s four lead PDCs. Once Theralase selects the final lead PDC at the end of the fourth quarter 2014, SAFC will manufacture both a 100-gram pre-Good Manufacturing Practice (“pre-GMP”) batch and finally a 500-gram GMP batch of the PDC. This final 500-gram batch is intended to be suitable for final sterilization and packaging into individual patient doses for safety and efficacy evaluation through a Health Canada / FDA Phase I/IIa clinical trial, expected in early 2015.
SAFC is Theralase’s partner of choice to provide a continuous supply of the lead PDC for future clinical trials and eventually commercialization of the PDC for human bladder cancer applications.
Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, “Theralase is delighted that we have partnered with SAFC in the development and manufacture of our PDCs, as they have the depth and experience to execute on the manufacture of our PDCs, quickly, efficiently and in whatever quantity is required. SAFC brings a very sophisticated and experienced team of analytical and developmental chemists to the table, whose expertise will prove indispensable in the development and commercialization of our anti-cancer technology.”
Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. stated that, “SAFC has been selected as our chosen partner in the development of our PDC platform because of their manufacturing expertise. I was extremely impressed with the knowledge and experience that their team brings to the development of our PDCs.”
About Theralase Technologies Inc.
Founded in 1994, Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners such as: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been very successful in healing nerve, muscle and joint conditions in clinical practice and now Theralase’s scientists are investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to the DNA of cancer cells and then, when light activated, destroy the cancer cells.
Additional information is available at www.theralase.com and www.sedar.com.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com